Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible

Next Previous
Trial Profile

A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PIVOT IO 009
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 31 Aug 2023 This trial has been completed in Poland (End Date: 09 Jun 2023), according to European Clinical Trials Database record.
  • 05 Jul 2023 This trial has been completed in Czechia, France and Netherlands (End Date: 09 Jun 2023), according to European Clinical Trials Database record.
  • 16 Mar 2023 This trial has been completed in Germany.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top